EU backs AstraZeneca drug for Covid treatment | kuwaittimes

EU backs AstraZeneca drug for Covid treatment

September 16, 2022 | 01:41 p.m EDT

London: AstraZeneca's Evusheld drug has been recommended for marketing in the European Union to treat patients at risk of death from Covid, the British pharmaceutical group said Friday.

The EU's drug watchdog had already approved Evusheld for the prevention of coronavirus in such patients.

"Evusheld long-acting antibody combination" has been "recommended for approval in the EU for the treatment of Covid-19", AstraZeneca said in a statement.

Its use via injection is recommended for adults and children aged 12 and above "who are at increased risk of progressing to severe Covid‑19", it added.

The European Medicines Agency's latest Evusheld recommendation followed trials showing "significant protection against progression to severe Covid-19 or death".

European Union COVID-19 AstraZeneca

September 16, 2022 01:41 PM

Opinion

Long-term multiple entry Schengen visa for GCC countries

Opinion

War, peace and unity

Educating for tomorrow: Addressing AI challenges

The rapid and widespread development of technology has led to the emergence of a generation that struggles to keep pace with the latest advancements in science. In the past, illiteracy and ignorance were primarily defined by the inability to read an...

Where is Kuwait’s beauty?

The measure of success for strategic plans lies in active participation in the implementation process. Conversely, centralization signifies failure. In Kuwait, we have six governorates, each delineated by clear boundaries marked by signs in the stre...